ArticleThe Journal of clinical investigation2002
Tr1 cell-dependent active tolerance blunts the pathogenic effects of determinant spreading.
Article in The Journal of clinical investigation, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 65 citations in OpenAlex.
- Regulatory T Cell-Based Adoptive Cell Therapy in Autoimmunity.International journal of molecular sciences · 2025Review
- Immune Modulation by Antigenic Peptides and Antigenic Peptide Conjugates for Treatment of Multiple Sclerosis.Medical research archives · 2022Article
- Serum levels of CC chemokine ligands in cutaneous leishmaniasis patients.Journal of parasitic diseases : official organ of the Indian Society for Parasitology · 2021Article
- Resolution of inflammation during multiple sclerosis.Seminars in immunopathology · 2019Review
- ITK signalling via the Ras/IRF4 pathway regulates the development and function of Tr1 cells.Nature communications · 2017Article
- CCR8Proceedings of the National Academy of Sciences of the United States of America · 2017Article
- Differentiation and Transmigration of CD4 T Cells in Neuroinflammation and Autoimmunity.Frontiers in immunology · 2017Review
- Induction of Peripheral Tolerance in Ongoing Autoimmune Inflammation Requires Interleukin 27 Signaling in Dendritic Cells.Frontiers in immunology · 2017Article
- Mechanisms of immunological tolerance in central nervous system inflammatory demyelination.Clinical & experimental neuroimmunology · 2015Article
- T cell subsets and their signature cytokines in autoimmune and inflammatory diseases.Cytokine · 2015Review
- Regulatory T-cell vaccination independent of auto-antigen.Experimental & molecular medicine · 2014Review
- Liver type I regulatory T cells suppress germinal center formation in HBV-tolerant mice.Proceedings of the National Academy of Sciences of the United States of America · 2013Article
- Type 1 regulatory T cells (Tr1) in autoimmunity.Seminars in immunology · 2011Review
- Article
- Antigen-specific CD25- Foxp3- IFN-gamma(high) CD4+ T cells restrain the development of experimental allergic encephalomyelitis by suppressing Th17.The American journal of pathology · 2010Article
- Article
- Naturally occurring and inducible T-regulatory cells modulating immune response in allergic asthma.American journal of respiratory and critical care medicine · 2009Article
- CXCL12 (SDF-1alpha) suppresses ongoing experimental autoimmune encephalomyelitis by selecting antigen-specific regulatory T cells.The Journal of experimental medicine · 2008Article
- IL-10-dependent infectious tolerance after the treatment of experimental allergic encephalomyelitis with redirected CD4+CD25+ T lymphocytes.Proceedings of the National Academy of Sciences of the United States of America · 2005Article
- Regulating the immune system: the induction of regulatory T cells in the periphery.Arthritis research & therapy · 2004Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Experimental autoimmune encephalomyelitis (EAE) is a T cell-mediated autoimmune disease of the CNS. The current study shows that even in an acute episode of disease the autoimmune response spreads from one determinant on myelin basic protein (MBP) to the other linked determinant and that this spread plays a functional role in the pathogenesis of disease. The soluble form of each determinant could be used to induce Ag-specific T cell tolerance and reverse an ongoing disease. We show that the rapid effect of soluble peptide therapy is due to repolarization of autoimmune T cells undergoing activation. We suggest that at least two different types of regulatory T cells participate in the induction of active tolerance. The first, yet to be fully characterized, functions in an IL-4-dependent manner. The second produces high levels of IL-10 and low levels of IL-4 (Tr1). We bring about completing evidence showing that these Tr1 cells play a pivotal role in the regulation of T cell tolerance during determinant spread and that soluble peptide therapy with the determinant to which the autoimmune response spreads amplifies a de novo regulatory mechanism aimed to reduce the pathological consequences of determinant spreading.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.